Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 3/20 | 0.35 |
| ▸ | TGM2 | P21980 | 2/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP9X | Q93008 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993437 | 0.83 | HTR6 (0.49) | HTR6BCHE | |
| SCHEMBL4260445 | 0.82 | PIK3CD (0.39) | USP30PIK3CDSTSMEN1KMT2A | |
| SCHEMBL1998793 | 0.81 | HTR6 (0.51) | HTR6LMNAPKMPKLR | |
| Trifluoroacetic Acid SCHEMBL4419171 | 0.77 | RORC (0.34) | HTR6 | |
| SCHEMBL4566492 | 0.77 | HTR6 (0.46) | HTR6BCHE | |
| Trifluoroacetic Acid SCHEMBL1998224 | 0.72 | HTR6 (0.40) | HTR6PKMPKLR | |
| SCHEMBL1995997 | 0.70 | HTR6 (0.47) | HTR6PKMPKLR | |
| SCHEMBL3276273 | 0.70 | UCHL1 (0.49) | USP30SMN1; SMN2MAPK1 | |
| SCHEMBL3330566 | 0.69 | HTR6 (0.50) | HTR6BCHESTSMEN1KMT2A | |
| SCHEMBL19667310 | 0.69 | USP2 (0.44) | USP30LMNASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960374-B2 | e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics | PROXIMAGEN LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20080176829-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176829-A1 | Compounds | HTR6, HTR1B, HTR1A | HTR6 1/4885USP30 3930/4885PIK3CD 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.